What is the recommended use of non‑selective beta‑blockers (e.g., propranolol) in hemodynamically stable adult patients with traumatic brain injury who have no contraindications?

Beta-Blockers for Traumatic Brain Injury

In hemodynamically stable adult patients with severe traumatic brain injury and no contraindications, beta-blockers—particularly propranolol—should be administered during hospitalization, as they reduce mortality by approximately 60% without significant adverse effects. 1

Guideline Recommendation

The Eastern Association for the Surgery of Trauma (EAST) 2017 guideline provides a conditional recommendation for in-hospital beta-blocker use in adults with acute TBI based on a systematic review and meta-analysis of 9 studies encompassing over 8,000 patients. 1 The evidence demonstrates:

• 61% reduction in mortality (pooled OR 0.39,95% CI: 0.27–0.56, p<0.00001) 1
• Very low quality of evidence due to observational study design
• No data on functional outcomes or quality of life measures
• Minimal reported cardiopulmonary adverse events

Clinical Implementation Algorithm

Patient Selection Criteria:

• Severe TBI (Head AIS 4-5, typically GCS ≤8) requiring ICU admission 1
• Hemodynamically stable at time of initiation
• No contraindications to beta-blockers

Critical Safety Parameters (Must Avoid):

• Hypotension: Systolic blood pressure <90 mmHg 1
• Symptomatic bradycardia: Heart rate <50 with symptoms 1

Timing and Dosing:

While the guideline cannot specify exact protocols, recent high-quality research provides practical guidance:

• Early initiation (within 24-48 hours) appears most beneficial 2, 3
• Propranolol specifically shows superiority over other beta-blockers 4
• Typical dosing: 20 mg orally every 12 hours (from RCT data) 5
• Continue throughout hospitalization (average 3 weeks in practice) 6

Supporting Evidence from Recent Research

The most recent and highest-quality study—a 2020 prospective randomized controlled trial (n=219)—demonstrated that in isolated severe TBI, propranolol significantly reduced:

• In-hospital mortality: 4.4% vs 18.6% (adjusted IRR 0.32, p=0.04) 5
• Improved 6-month functional outcomes (GOS-E ≥5, adjusted IRR 1.2, p=0.02) 5

A 2018 multicenter prospective observational study (n=2,252) from the American Association for the Surgery of Trauma confirmed:

• Lower mortality with beta-blockers (13.8% vs 17.7%, adjusted OR 0.35, p<0.001) 4
• Propranolol superior to other beta-blockers (adjusted HR 0.50, p=0.003) 4

Mechanism of Benefit

TBI triggers a hyperadrenergic state with elevated local norepinephrine levels and increased cerebral metabolic rate for oxygen and glucose. 1 This exacerbates ischemia and metabolic crisis in the injured brain with defective autoregulation. Beta-blockers, particularly propranolol (which crosses the blood-brain barrier), blunt this sympathetic cascade. 1, 3

Recent mechanistic data (2026) shows propranolol:

• Reduces peripheral neutrophil and classical monocyte production 7
• Inhibits inflammatory cell infiltration into the brain 7
• Reverses inflammatory transcriptomic profiles in bone marrow and brain 7

Important Caveats and Pitfalls

Evidence Quality Concerns:

The guideline acknowledges very low quality evidence due to:

• Predominantly retrospective observational studies 1
• Substantial heterogeneity (I²=65%) 1
• Lack of data on functional outcomes in most studies 1
• No standardized dosing, timing, or duration protocols 1

The "CRASH Trial" Warning:

The guideline authors explicitly caution against over-interpreting observational data, citing the corticosteroid story in TBI where promising meta-analyses were contradicted by the definitive CRASH trial. 1 However, unlike corticosteroids, subsequent RCT data for propranolol has been positive rather than contradictory. 5

Monitoring Requirements:

• ICU-level monitoring is essential to detect and prevent hypotension and bradycardia 1
• The recommendation is limited to severe TBI patients in ICU settings where cardiovascular monitoring is feasible 1
• Observed bradycardia occurs in 40% of patients but is generally manageable 6

Population-Specific Considerations:

• Most evidence comes from severe TBI populations 1
• Benefits in mild-moderate TBI remain unclear 8
• Isolated severe TBI shows clearer benefit than polytrauma 5
• Aged patients may experience attenuated systemic inflammation with propranolol 7

Divergent Evidence

A 2025 meta-analysis of RCTs only (n=559) found:

• No significant reduction in unfavorable neurological outcomes (RR 0.81,95% CI 0.57-1.15) 9
• Reduced mortality (RR 0.57,95% CI 0.39-0.82) 9
• Shorter mechanical ventilation duration 9

This highlights that while mortality benefits appear consistent, functional outcome data remains limited and conflicting—a critical gap since survival with severe disability may not represent meaningful benefit.

Practical Recommendation

For hemodynamically stable adults with severe TBI in the ICU without contraindications, initiate propranolol 20 mg orally every 12 hours within 24-48 hours of injury, maintaining systolic BP ≥90 mmHg and avoiding symptomatic bradycardia (HR <50 with symptoms). 1, 5, 3 This represents the best balance of available evidence prioritizing mortality reduction, though clinicians should counsel families that functional outcome data remains limited.

The recommendation is conditional rather than strong due to evidence quality limitations, but the consistency of mortality benefit across multiple studies, including recent RCT data, supports clinical use in appropriately selected and monitored patients. 1, 5, 4